Welcome to our dedicated page for Kura Oncology SEC filings (Ticker: KURA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Kura Oncology, Inc. (Nasdaq: KURA) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, including current reports, financial updates and material agreements. As a biopharmaceutical company focused on precision medicines for cancer, Kura uses these filings to report significant events related to its lead menin inhibitor program, KOMZIFTI (ziftomenib), and its broader pipeline.
Recent Form 8-K filings describe key milestones such as full U.S. Food and Drug Administration approval of KOMZIFTI for adult patients with relapsed or refractory acute myeloid leukemia with a susceptible NPM1 mutation, clinical data from the pivotal KOMET-001 trial, and the wholesale acquisition cost for a one-month supply of KOMZIFTI. Other 8-Ks outline collaboration and co-promotion agreements with Kyowa Kirin, including terms under which Kura leads development, regulatory and commercial strategy in the United States while Kyowa Kirin leads efforts outside the United States.
Filings also cover financial results releases under Item 2.02, inducement equity plans and amendments, and milestone payments associated with the KOMET-017 Phase 3 registrational trials. These documents provide insight into Kura’s commercialization of KOMZIFTI, its clinical development plans for ziftomenib in newly diagnosed and relapsed or refractory AML, and its farnesyl transferase inhibitor programs.
On Stock Titan, investors can review KURA’s SEC filings alongside AI-powered summaries that highlight the main points of each document. This includes quick views of material events, collaboration structures, and key clinical or regulatory disclosures, helping users navigate detailed 8-Ks and related exhibits without reading every line.
Brian T. Powl, Chief Commercial Officer and director at Kura Oncology (KURA), reported receipt of 48,900 shares of common stock from a vesting equity award on 09/27/2025 at no cash price, increasing his beneficial ownership to 108,567 shares. On 09/29/2025 he sold 8,891 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes related to the vesting, leaving him with 99,676 shares beneficially owned. The Form 4 was submitted by a single reporting person and includes an attorney-in-fact signature on behalf of the reporting person.
Teresa Brophy Bair, Chief Legal Officer and director of Kura Oncology, reported two transactions tied to performance-based restricted stock units. On September 27, 2025 1/6th of PSUs vested after the company determined that one specified development milestone was met, resulting in the acquisition of 48,900 shares at a $0 price and increasing her beneficial ownership to 156,848 shares. On September 29, 2025 she executed a sell-to-cover tax transaction, selling 8,805 shares at $8.9422 per share, leaving 148,043 shares beneficially owned. The Form 4 was signed by an attorney-in-fact, Thomas Doyle, on September 29, 2025.
Kathleen Ford, Chief Operating Officer of Kura Oncology (KURA), reported the vesting of performance-based restricted stock units after one development milestone was met on 09/27/2025. The filing shows acquisition by vesting of 48,900 shares (price $0) which increased her beneficial ownership to 70,267 shares, followed by a sell-to-cover transaction of 6,892 shares on 09/29/2025 at $8.9422 per share, leaving 63,375 shares beneficially owned. The sale is disclosed as tax withholding related to the vesting of 1/6th of the underlying PSUs from a grant dated 05/31/2023.
Kura Oncology Chief Medical Officer Mollie Leoni received 82,500 shares of common stock upon vesting of performance-based restricted stock units tied to a development milestone achieved on 09/27/2025. Immediately following, 12,314 shares were sold on 09/29/2025 at a price of $8.9422 per share to cover taxes, leaving the reporting person with 158,439 shares beneficially owned. The filing states each PSU converts to one share if performance and service conditions are met; 1/6th of the grant vested when a milestone was met. Transactions were reported on a Form 4 by one reporting person.
Troy E. Wilson, President and CEO and a director of Kura Oncology (KURA), reported the vesting of performance-based restricted stock units and a related sell-to-cover tax sale. On 09/27/2025 182,500 shares were acquired upon the vesting of 1/6th of PSUs granted May 31, 2023 (price reported $0). On 09/29/2025 the reporting person sold 36,615 shares at $8.9422 per share to cover taxes, leaving 246,853 shares held directly. The filing also shows 279,194 shares held indirectly by One Fish Two Fish Revocable Trust and 300,000 shares held indirectly by Lorax Charitable Remainder Unitrust.
Kura Oncology SVP, Finance & Accounting Thomas Doyle acquired 24,966 shares of Kura common stock on 09/27/2025 at a reported price of $0, increasing his direct holdings to 114,370 shares. On 09/29/2025 he sold 4,541 shares at $8.9422 per share as a sell-to-cover transaction to satisfy taxes tied to the vesting of 1/6th of performance-based restricted stock units (PSUs). The filing notes that one performance milestone was achieved on 09/27/2025, triggering the vesting event for that tranche; the Reporting Person also reports 500 shares indirectly held in a spouse's 401(k). After the transactions the Reporting Person beneficially owns 109,829 shares.
Reporting person: Troy Edward Wilson, President & CEO and a director of Kura Oncology, Inc. (KURA). On 09/08/2025 he acquired 50,000 shares of the issuer's common stock in multiple trades at a weighted average purchase price of $8.2029 per share. After the purchase, Mr. Wilson beneficially owns 100,968 shares directly and holds additional indirect interests of 279,194 shares through the One Fish Two Fish Revocable Trust and 300,000 shares through the Lorax Charitable Remainder Unitrust. The Form 4 was signed by an attorney-in-fact on behalf of Mr. Wilson on 09/09/2025. The filing discloses that trade prices ranged from $8.135 to $8.24 and that the reported price is a weighted average.
Armistice Capital, LLC and Steven Boyd report shared beneficial ownership of 6,200,000 shares of Kura Oncology common stock, representing 7.14% of the class based on 86,797,185 shares outstanding as reported by the issuer. The shares are directly held by Armistice Capital Master Fund Ltd., for which Armistice Capital acts as investment manager and exercises shared voting and dispositive power over the reported shares. Both Armistice Capital and Mr. Boyd state no sole voting or dispositive power and that the Master Fund disclaims beneficial ownership due to the manager’s control under the investment management agreement. The filing is made on behalf of both reporting persons under a joint filing statement.
Troy Edward Wilson, President, CEO and a director of Kura Oncology, purchased additional common stock on 08/12/2025 and 08/13/2025. On 08/12/2025 he acquired 36,506 shares at a weighted average price of $5.8505. On 08/13/2025 he acquired 13,494 shares at a weighted average price of $6.6417. Following these purchases the reporting person directly beneficially owns 50,968 shares. The filing discloses indirect holdings of 279,194 shares held by the One Fish Two Fish Revocable Trust and 300,000 shares held by the Lorax Charitable Remainder Unitrust. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on 08/13/2025. Explanatory notes state the trades were executed in multiple fills and include 409 shares previously acquired on 05/17/2024 under the issuer's Employee Stock Purchase Plan.
EcoR1 Capital, EcoR1 Capital Fund Qualified, L.P. and Oleg Nodelman jointly reported beneficial ownership of Kura Oncology common stock on a Schedule 13G/A. EcoR1 and Mr. Nodelman each report shared voting and shared dispositive power over 4,200,000 shares, representing 4.8% of the outstanding common stock, while the Qualified Fund reports shared voting and dispositive power over 3,937,232 shares, representing 4.5%.
The filing states these interests were acquired and are held in the ordinary course of business and were not acquired to influence control of the issuer. The filing also discloses that EcoR1 is the general partner and investment adviser to funds including the Qualified Fund and that Mr. Nodelman is the control person of EcoR1. Percentages are calculated using 86,797,185 shares outstanding as reported in the issuer's quarter-end filing.